Drug Shortage Report for SANDOZ RIVASTIGMINE
Report ID | 169694 |
Drug Identification Number | 02324601 |
Brand name | SANDOZ RIVASTIGMINE |
Common or Proper name | RIVASTIGMINE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | RIVASTIGMINE |
Strength(s) | 6MG |
Dosage form(s) | CAPSULE |
Route of administration | ORAL ORAL |
Packaging size | 56HGC |
ATC code | N06DA |
ATC description | ANTI-DEMENTIA DRUGS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-09-21 |
Estimated end date | 2022-10-21 |
Actual end date | 2022-10-04 |
Shortage status | Resolved |
Updated date | 2022-10-05 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-10-05 | English | Compare |
v5 | 2022-10-04 | French | Compare |
v4 | 2022-10-04 | English | Compare |
v3 | 2022-09-22 | English | Compare |
v2 | 2022-09-21 | French | Compare |
v1 | 2022-09-21 | English | Compare |
Showing 1 to 6 of 6